Short Interest in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Expands By 1,418.5%

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the target of a significant growth in short interest in the month of June. As of June 30th, there was short interest totaling 114,234 shares, a growth of 1,418.5% from the June 15th total of 7,523 shares. Based on an average trading volume of 53,894 shares, the days-to-cover ratio is presently 2.1 days. Approximately 7.6% of the company’s shares are sold short.

Global X Genomics & Biotechnology ETF Trading Down 3.2%

NASDAQ:GNOM traded down $1.89 during trading hours on Friday, hitting $56.65. 33,529 shares of the stock traded hands, compared to its average volume of 14,357. The firm has a 50 day moving average price of $50.36 and a 200 day moving average price of $47.61. The firm has a market cap of $85.54 million, a price-to-earnings ratio of -24.21 and a beta of 1.16. Global X Genomics & Biotechnology ETF has a fifty-two week low of $34.04 and a fifty-two week high of $59.48.

Global X Genomics & Biotechnology ETF Dividend Announcement

The firm also recently declared a dividend, which was paid on Tuesday, July 7th. Stockholders of record on Monday, June 29th were issued a dividend of $0.0579 per share. The ex-dividend date was Monday, June 29th. Global X Genomics & Biotechnology ETF’s payout ratio is currently -27.35%.

Institutional Investors Weigh In On Global X Genomics & Biotechnology ETF

Several hedge funds have recently bought and sold shares of GNOM. U.S. Capital Wealth Advisors LLC bought a new stake in shares of Global X Genomics & Biotechnology ETF in the 4th quarter valued at approximately $575,000. IFP Advisors Inc raised its position in Global X Genomics & Biotechnology ETF by 20.8% during the third quarter. IFP Advisors Inc now owns 2,835 shares of the company’s stock valued at $110,000 after acquiring an additional 489 shares in the last quarter. Jane Street Group LLC lifted its stake in Global X Genomics & Biotechnology ETF by 7.7% in the first quarter. Jane Street Group LLC now owns 143,713 shares of the company’s stock valued at $1,143,000 after acquiring an additional 10,308 shares during the last quarter. Sei Investments Co. lifted its stake in Global X Genomics & Biotechnology ETF by 110.4% in the second quarter. Sei Investments Co. now owns 23,073 shares of the company’s stock valued at $194,000 after acquiring an additional 12,105 shares during the last quarter. Finally, Smartleaf Asset Management LLC lifted its stake in Global X Genomics & Biotechnology ETF by 30.9% in the second quarter. Smartleaf Asset Management LLC now owns 19,548 shares of the company’s stock valued at $164,000 after acquiring an additional 4,615 shares during the last quarter. 56.95% of the stock is owned by hedge funds and other institutional investors.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.